View Clause Headings                                                                                                                                               HelpHelp
DOCUMENT TITLE:  LICENSE AND COLLABORATION AGREEMENT .
ACTIONS: Here are the clause headings in the document. To view the clause, click the clause heading.To view the full document, click the "View Document" button.

View Document Back
Clause Heading
ARTICLE II - GRANT OF RIGHTS;
(a) - License Grants to Licensee.
(b) - Sublicense Rights.
2.2 - No Other Rights.
(a) - Pre-Existing Alliance Agreements.
(b) - Contractual Obligations under Listed Alnylam Third Party Agreements.
(a) - Blocked Targets.
(b) - Gatekeeper.
(a) - Additional Fields.
(b) - Field Option.
2.6 - Designated Target Option.
(a) - Compliance with Novartis Agreement.
(b) - Alnylam Change of Control.
(c) - No Adverse Amendments.
(d) - Specific Performance.
(a) - Claimed Infringement.
(b) - Trademarks.
(c) - Enforcement of Licensed Intellectual Property.
(d) - Notice of Changes.
2.9 - Obligation to Maintain Listed Alnylam Third Party Agreements.
ARTICLE III - TECHNOLOGY TRANSFER;
(a) - Initial Technology Transfer.
(b) - Technology Transfer to Alnylam After Technology Transfer Period.
(c) - Management of Transition Activities.
(d) - Additional Services.
3.2 - Joint Future Technology Committee.
4.1 - Discovery Collaboration.
4.2 - Minimum Terms.
5.1 - Equity Investment.
5.2 - License Grant Consideration.
(a) - Development Events.
(b) - Sales Events.
(c) - Achievement of Events.
(d) - Event Payments Payable Only Once.
(a) - Royalty Rate.
(b) - Expiration of Patent Coverage.
(c) - Royalty Stacking.
(d) - Payments in Respect of Alnylam In-Licenses.
(e) - Deductions.
(f) - Loss of Listed Alnylam Third Party Agreements.
(g) - Duration of Royalty Payments; First Commercial Sale.
5.6 - Field Option Fee.
5.7 - Most Favored Licensee.
5.8 - Payment of Royalty.
5.9 - Currency Computation.
5.10 - Reporting.
5.11 - Withholding Taxes.
5.12 - Financial Records.
5.13 - Audits by Alnylam.
5.14 - Late Payments.
6.1 - Confidential Information.
6.2 - Employee and Advisor Obligations.
6.3 - Publicity.
(a) - Representations of Authority.
(b) - Consents.
(c) - No Conflict.
(d) - Authorization and Binding Nature.
(e) - Employee Obligations.
7.2 - Representations and Warranties of Alnylam.
(a) - Organization and Good Standing.
(b) - Non-Infringement.
(c) - Validity.
(d) - Litigation.
(e) - Authority.
(f) - Certain Exclusive Rights.
(g) - Listed Alnylam Third Party Agreements.
(h) - Pre-Existing Alliance Agreements.
(i) - Isis.
(j) - Protecting IP Rights.
(k) - Completeness.
(l) - Forthrightness.
7.3 - Representations and Warranties of Licensee.
7.4 - No Warranties.
8.1 - Term.
8.2 - Termination for Cause.
8.3 - Termination for Patent Challenge.
8.4 - Termination At Will.
8.5 - Effect of Expiration or Termination.
(a) - Termination by Licensee For Alnylam Breach.
(c) - Paid-Up License.
(d) - Survival.
(a) - By Alnylam.
(b) - By Licensee.
9.2 - Choice of Law.
9.3 - Notices.
9.4 - Severability.
9.5 - Interpretation.
9.6 - Integration.
9.7 - Independent Contractors; No Agency.
9.8 - Assignment; Successors.
9.9 - Execution in Counterparts; Facsimile Signatures.
9.10 - Waivers.
9.11 - No Consequential or Punitive Damages.
9.12 - Actions of Affiliates.
9.13 - Expenses.
9.14 - No Third Party Beneficiaries.
9.15 - Alnylam Europe AG.
9.16 - Bankruptcy.
I - United States Patents and Applications
I - United States Patents and Applications